Sex hormone preparations and retinal vein occlusion

Eye

Volumn 11, Issue 1, 1997, Pages 53-56

  Kirwan, J F ^a   Tsaloumas, M D ^b   Vinall, H ^c   Prior, P ^c   Kritzinger, E E ^b   Dodson, P M ^c  

^a KINGSTON HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; SEX HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; RETINA VEIN OCCLUSION;

EID: 0031001995     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.1997.11     Document Type: Article

References (23)

1. Sorsby A. The incidence and causes of blindness in England and Wales. London: HMSO, 1978:1963-8.
2. Klein BA. Occlusion of the central retinal vein: clinical importance of certain histo-patholoaic observations. Am J Ophthalmol 1953;36:316-24.
3. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis: a pathological report. Trans Ophthalmol Soc UK 1968;88:191-210.
4. Dodson PM, Kritzinger EE. Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophihalmol Soc UK 1985;104:114-9.
5. Vessey MP. Female hormones and vascular disease: an epidemiological overview. Br J Fam Plann 1980;6:1-12.
6. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91-5.
7. Vessey MP, Lawless M, Yeates D. Oral contraceptives and stroke: findings in a largo prospective study. BMJ 1984;289:530-1.
8. La Veccia C. Sex hormones and cardiovascular risk. Hum Reprod 1992;7:162-7.
9. Grimes DA. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992;166:1950-4.
10. Thorogood M, Villard-Macintosh L. Combined oral contraceptives: risks and benefits. Br Med Bull 1993;49:124-39.
11. Foster K, Jackson B, Thomas M, Hunter P, Bennett N. Contraception. In: General household survey. London: HMSO, 1993:113-36.
12. Godsland IF, Crook D, Wynn V. Clinical and metabolic considerations of long term oral contraceptive use. Am J Obstet Gynecol 1992;166:1955-63.
13. Fong ACO, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393-417.
14. Cecily C, Kelleher MD. Clinical aspects of the relationship between oral contraceptives and abnormalities of the coagulation system: relation to the development of cardiovascular disease. Am J Obstet Gynecol 1990;163:392-5.
15. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gvnecol 1987;157:1042-8.
16. Prentice RL. On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. Am J Epidemiol 1988;127:213-9.
17. Wynn V, Adams PW, Godsland I, et al. Comparison of effects of different combined oral-contraceptives on carbohydrate and lipid metabolism. Lancet 1979;1:1049-54.
18. Fotherby K. Update on lipid metabolism and oral contraception. Br J Fam Plann 1990;15:23-6.
19. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;61:592-5.
20. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276-308.
21. Lobo RA. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 1992;166:1997-2003.
22. Meade TW, Stanwell-Smith R. Hormone replacement therapy for menopausal women: a review of its effects on homeostalic function, lipids, and blood pressure. Adv Drug Reac Rev 1984;4:187-210.
23. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994;8:491-4.